---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026333"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:17:10.308718+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio presents preclinical data for sequencing method to measure gene editing outcomes in sickle cell

## Summary
- Preclinical data presented at ASH on single-cell RNA sequencing method to assess gene correction in reticulocytes.
- Method accurately differentiated AA, AS, and SS reticulocytes in proof-of-concept mixtures.
- Method will be used to measure gene editing outcomes in patients treated with nula-cel (GPH101) for sickle cell disease.
- Nula-cel is being evaluated in the CEDAR Phase 1/2 trial with Fast Track and Orphan Drug designations.

## SEC filing metadata
- accession: 0000950170-22-026333
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017022026333/0000950170-22-026333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017022026333/grph-20221211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026333
- JSON: https://secwatch.observer/filing/0000950170-22-026333.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.